Access Bio, Inc. Logo

Access Bio, Inc.

Develops and manufactures rapid diagnostic tests for infectious diseases for global health.

950130 | KO

Overview

Corporate Details

ISIN(s):
KR8840090003
LEI:
Country:
United States of America
Address:
65 Clyde Road Suite A, Somerset NJ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Access Bio, Inc. is a biotechnology company dedicated to the prevention and early diagnosis of infectious diseases. It engages in the research, development, manufacturing, and marketing of in vitro rapid diagnostic tests (IVD), biosensors, and molecular diagnostic products. The company is a key partner in global health, recognized for its comprehensive portfolio of tests for diseases such as malaria, HIV, HPV, and COVID-19. Through its products, including the CareStart™ line, Access Bio focuses on providing high-quality, accessible diagnostic solutions to combat serious health threats worldwide, particularly in developing nations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-08-18 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내 )
Korean 3.0 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.8 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.1 MB
2025-08-14 00:00
Earnings Release
반기또는분기매출액미달사실발생
Korean 6.0 KB
2025-08-14 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 관련)
Korean 3.2 KB
2025-08-14 00:00
Delisting Announcement
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-05-20 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 26.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 88.3 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.5 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.6 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 26.7 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.8 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.7 KB

Automate Your Workflow. Get a real-time feed of all Access Bio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Access Bio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Access Bio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS

Talk to a Data Expert

Have a question? We'll get back to you promptly.